Stockscreener 앱 받기
17.16
0.41%
0.07
시간 외 거래:
17.16
전일 마감가:
$17.09
열려 있는:
$17.05
하루 거래량:
744.40K
Relative Volume:
0.85
시가총액:
$1.81B
수익:
-
순이익/손실:
$-150.70M
주가수익비율:
-11.07
EPS:
-1.55
순현금흐름:
$-125.67M
1주 성능:
-6.13%
1개월 성능:
+13.34%
6개월 성능:
+18.18%
1년 성능:
-51.57%
1일 변동 폭
$16.70
$17.65
1주일 범위
$16.70
$18.61
52주 변동 폭
$10.60
$38.12
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
EWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
17.16 | 1.80B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics (EWTX): RBC Capital Raises Price Target to - GuruFocus
Does Edgewise Therapeutics Inc. show high probability of reboundWeekly Volume Report & Target Return Focused Picks - newser.com
What valuation multiples suggest for Edgewise Therapeutics Inc. stockBuy Signal & Technical Pattern Based Signals - newser.com
RBC Adjusts Price Target on Edgewise Therapeutics to $50 From $49, Maintains Outperform Rating - MarketScreener
How to track smart money flows in Edgewise Therapeutics Inc.Quarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Real time breakdown of Edgewise Therapeutics Inc. stock performanceOptions Play & High Accuracy Swing Trade Signals - newser.com
Wedbush Lowers Price Target on Edgewise Therapeutics to $32 From $35, Keeps Outperform Rating - MarketScreener
Edgewise Therapeutics (NASDAQ: EWTX) sets Nov–Dec investor fireside chats; webcasts - Stock Titan
Edgewise Therapeutics Inc. stock prediction for this weekJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - newser.com
Risk vs reward if holding onto Edgewise Therapeutics Inc.July 2025 Pullbacks & Low Drawdown Investment Strategies - newser.com
Edgewise Therapeutics Reports Q3 2025 Financial Results - TipRanks
Decoding Edgewise Therapeutics Inc (EWTX): A Strategic SWOT Insi - GuruFocus
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Edgewise Therapeutics' Q3 Net Loss Widens, Beats Estimate; Shares Rise - MarketScreener
Edgewise Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q3 Net Loss $0.39 a Share, vs. FactSet Est of $0.42 Loss - MarketScreener
Edgewise Therapeutics Q3 net loss widens as R&D costs rise - MarketScreener
[8-K] Edgewise Therapeutics, Inc. Reports Material Event | EWTX SEC FilingForm 8-K - Stock Titan
[10-Q] Edgewise Therapeutics, Inc. Quarterly Earnings Report | EWTX SEC FilingForm 10-Q - Stock Titan
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Chart overlay techniques for tracking Edgewise Therapeutics Inc.2025 Market Trends & Weekly High Return Stock Forecasts - newser.com
Is Edgewise Therapeutics Inc. stock supported by innovation pipelineJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
Multi asset correlation models including Edgewise Therapeutics Inc.Volume Spike & Verified Chart Pattern Signals - newser.com
Strategies to average down on Edgewise Therapeutics Inc.2025 Dividend Review & Verified Entry Point Detection - newser.com
Real time alert setup for Edgewise Therapeutics Inc. performancePortfolio Return Report & Smart Money Movement Alerts - newser.com
What hedge fund activity signals for Edgewise Therapeutics Inc. stock2025 Market Sentiment & Growth Focused Investment Plans - newser.com
Is Edgewise Therapeutics Inc. trending in predictive chart modelsPortfolio Return Report & Free Technical Confirmation Trade Alerts - newser.com
Risk adjusted return profile for Edgewise Therapeutics Inc. analyzedJuly 2025 Review & Capital Efficiency Focused Strategies - newser.com
How Edgewise Therapeutics Inc. stock reacts to oil pricesPortfolio Update Report & Long-Term Capital Growth Ideas - fcp.pa.gov.br
Detecting price anomalies in Edgewise Therapeutics Inc. with AIEarnings Overview Report & Growth Focused Entry Point Reports - newser.com
Published on: 2025-11-05 01:23:25 - newser.com
Exit strategy if you’re trapped in Edgewise Therapeutics Inc.Options Play & Daily Growth Stock Tips - newser.com
Published on: 2025-11-04 23:53:31 - newser.com
Analyzing Edgewise Therapeutics Inc. with risk reward ratio charts2025 Momentum Check & Safe Capital Growth Tips - newser.com
How Edgewise Therapeutics Inc. stock performs in stagflationJuly 2025 Sector Moves & Stepwise Trade Execution Plans - newser.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Lelezard
Truist Securities reiterates Buy rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics prepares for pivotal research in cardiovascular medicine - Traders Union
Can Edgewise Therapeutics Inc. stock beat analyst upgradesJuly 2025 Trade Ideas & Daily Technical Forecast Reports - newser.com
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.44%
0.70%
자본화:
|
볼륨(24시간):